Skin Cancer

Combos Lead Excitement in BRAF+ Melanoma, but More Pain Points are Ready to be Tackled
March 30, 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Uveal Melanoma
March 29, 2021

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

Combination Treatment Improves Relapse-Free Survival Time
March 25, 2021

Treatment pairing dabrafenib and trametinib could have expanded benefits for patients with melanoma.